Ito A, Egashira K, Kadokami T, Fukumoto Y, Takayanagi T, Nakaike R, Kuga T, Sueishi K, Shimokawa H, Takeshita A
Research Institute of Angiocardiology, Kyushu University School of Medicine, Fukuoka, Japan.
Circulation. 1995 Nov 1;92(9):2636-44. doi: 10.1161/01.cir.92.9.2636.
Endothelium-derived nitric oxide (NO) is believed to regulate myocardial perfusion and structural changes in the vascular wall. Our objective was to determine whether chronic inhibition of NO synthesis causes structural and functional changes in coronary arteries.
Coronary vasomotor response was studied in pigs before and after chronic oral administration of the NO synthesis antagonist N omega-nitro-L-arginine methyl ester (L-NAME) 30 mg.kg-1.d-1 for 2 weeks. Chronic L-NAME treatment increased (P < .01) arterial pressure but did not alter baseline coronary blood flow (CBF), epicardial coronary diameter, or heart rate. Chronic L-NAME treatment augmented (P < .01) the decrease in CBF in response to intracoronary serotonin (30 micrograms/kg) from 5 +/- 14% to 40 +/- 5% but did not alter the CBF response to prostaglandin F2 alpha. The serotonin-induced decrease in CBF after acute L-NAME administration was still less before (1.3 +/- 0.4%) than after chronic L-NAME treatment (51 +/- 6%). Chronic L-NAME treatment attenuated the increase in CBF with bradykinin (100 ng/kg) but did not alter the CBF response to nitroglycerin (10 micrograms/kg). Compared with intact pigs without L-NAME treatment, L-NAME-treated pigs had significant thickening of the media in the microvessels (diameter, < 300 microns) but not in the large epicardial vessels. Chronic intracoronary infusion of L-NAME at 3 mg.kg-1.d-1 for 2 weeks, which did not produce arterial hypertension, caused similar microvascular medial thickening.
These results indicate that chronic administration of L-NAME caused coronary microvascular structural changes and hyperreactivity to serotonin in pigs in vivo, suggesting an important role of defective NO synthesis in coronary microvascular disorders.
内皮衍生的一氧化氮(NO)被认为可调节心肌灌注及血管壁的结构变化。我们的目的是确定慢性抑制NO合成是否会导致冠状动脉的结构和功能改变。
对猪进行研究,在慢性口服给予NO合成拮抗剂Nω-硝基-L-精氨酸甲酯(L-NAME)30mg·kg⁻¹·d⁻¹持续2周前后,检测其冠状动脉血管舒缩反应。慢性L-NAME治疗使动脉压升高(P<.01),但未改变基础冠状动脉血流量(CBF)、心外膜冠状动脉直径或心率。慢性L-NAME治疗增强了(P<.01)冠状动脉内给予5-羟色胺(30μg/kg)后CBF的降低幅度,从5±14%增至40±5%,但未改变CBF对前列腺素F2α的反应。急性给予L-NAME后5-羟色胺诱导的CBF降低幅度在慢性L-NAME治疗前(1.3±0.4%)仍低于治疗后(51±6%)。慢性L-NAME治疗减弱了缓激肽(100ng/kg)引起的CBF增加,但未改变CBF对硝酸甘油(10μg/kg)的反应。与未接受L-NAME治疗的完整猪相比,接受L-NAME治疗的猪微血管(直径<300μm)中膜显著增厚,而大的心外膜血管未增厚。以3mg·kg⁻¹·d⁻¹的剂量冠状动脉内慢性输注L-NAME持续2周,虽未引起动脉高血压,但导致了类似的微血管中膜增厚。
这些结果表明,在体内慢性给予L-NAME可导致猪冠状动脉微血管结构改变及对5-羟色胺的反应性增强,提示NO合成缺陷在冠状动脉微血管疾病中起重要作用。